Our history

  • Open Targets celebrates 5-year anniversary

    June 2019

    Colleagues from all of our consortium partners gathered at the Wellcome Genome Campus in Hinxton, UK to celebrate 5 years of Open Targets and plan the milestones for our next 5 years.

  • Single cell lung map published in Nature Medicine

    June 2019

    Open Targets researchers map health and asthmatic lung tissue to uncover new drug targets for treating asthma

    Read the publication
  • Large-scale release of CRISPR data from Project Score publication

    April 2019

    Open Targets publishes results from its landmark experimental project where CRISPR technology was used in over 300 cancer models to discover thousands of key genes essential for cancer's survival.

    Read the publication
  • Ian Dunham appointed Open Targets Director

    January 2019

    Sanofi joins the consortium and brings its expertise in immunology, oncology, neurosciences and diabetes to help us identify potential drug targets.

    Read the press release
  • Sanofi joins Open Targets

    October 2018

    Sanofi joins the consortium and brings its expertise in immunology, oncology, neurosciences and diabetes to help us identify potential drug targets.

    Read the press release
  • Open Targets Genetics Portal beta release

    August 2018

    Prior to the official release at ASHG 2018, we released a beta version of the Genetics Portal allowing users to browse gene-variant-trait relationships from UK Biobank data and GWAS Catalog studies

    Explore the Genetics Portal
  • Celgene joins Open Targets

    May 2018

    Celgene joins Open Targets and brings its expertise in developing innovative therapies for patients with cancer, immune-inflammatory, and other unmet medical needs.

    Read the press release
  • Rolf Apweiler appointed Interim Director

    August 2018

    Rolf Apweiler becomes the Interim Director for Open Targets and continues to foster new partnerships and collaborations to drive drug discovery.

  • Takeda joins Open Targets

    December 2017

    Takeda joins Open Targets and brings its expertise in oncology, gastroenterology and central nervous system therapeutic areas, along with vaccines.

    Read the press release
  • New brand, new data: introducing Open Targets

    April 2016

    To celebrate the release of our first experimental data, CTTV rebrands itself as Open Targets but maintains its focus on helping researchers identify and prioritise potential therapeutic drug targets.

    Read the press release
  • Biogen joins Open Targets

    February 2016

    Biogen joins Open Targets and brings its expertise in innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.

    Read the press release
  • December 2015

    Target Validation Platform launched

    Underscoring our commitment to share our data openly to benefit the broader scientific community, we launched a new web platform to help researchers identify therapeutic targets for new and repurposed medicines.

    Read the press release
  • February 2015

    Jeffrey Barrett appointed founding Director

    After leading the development of the Immunochip genotyping array and playing an important role in UK10K, Dr Jeffrey Barrett is appointed as the founding Director of the Centre for Therapeutic Target Validation (CTTV).

    Read the press release
  • Centre for Therapeutic Target Validation launched

    March 2014

    The predecessor to Open Targets was founded in March 2014 when the European Bioinformatics Institute (EMBL-EBI), the Wellcome Sanger Institute, and GSK came together to build a partnership that would focus on target identification, prioritisation, and validation.

    Press release